Stocktoria
Senti Biosciences Holdings, Inc. SNTI
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-05-26
Senti Biosciences Holdings, Inc. financials (annual)
Bars are annual figures from 2021 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $22,000 | $0 | $2.6M | $4.3M | $2.8M |
| R&D expense | $37.6M | $34.4M | $32.1M | $28.1M | $22.0M |
| Operating income | -$68.8M | -$61.0M | -$92.7M | -$62.1M | -$40.4M |
| Income tax | $0 | $0 | — | — | — |
| Net income | -$61.4M | -$52.8M | -$71.1M | -$58.2M | -$55.3M |
| EPS (diluted) | $-2.73 | $-12.03 | $-16.01 | $-2.23 | $-19.00 |
| Operating cash flow | -$43.4M | -$41.4M | -$52.4M | -$34.9M | -$34.6M |
| Free cash flow | -$43.6M | -$41.4M | -$64.4M | -$76.3M | -$40.2M |
| Cash & equivalents | $16.4M | $48.3M | $35.9M | $57.6M | $56.0M |
| Total assets | $51.2M | $97.8M | $119.5M | $180.8M | $96.7M |
| Total liabilities | $45.6M | $47.1M | $52.6M | $53.5M | $36.3M |
| Shareholders' equity | $5.6M | $25.6M | $66.9M | $127.3M | -$111.5M |
Growth · year-over-year · Revenue CAGR -70.1%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue growth | — | -100.0% | -40.2% | +55.2% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.